

DAFTAR PUSTAKA

- Alba, L., Hay, J.E., Angulo, P., & Lee, W.M., 2002, Lactulose therapy in acute liver failure, *Journal of Hepatology*, **36**, 33.
- Almani, S.A., Memon, A.S., Memon, A.I., Shah, M.I., Rahpoto, M.Q., & Solangi, R., 2008, Cirrhosis of liver: Etiological factors, complications and prognosis, *Liaquat University of Medical & Health Sciences*, 61-66.
- Amarapurkar, D. N., 2011, Prescribing Medications in Patients with Decompensated Liver Cirrhosis, *International Journal of Hepatology*, 1-6.
- Amarapurkar, P.D., & Amarapurkar, D.N., 2011, Management of Coagulopathy in Patients with Decompensated Liver Cirrhosis, *International Journal of Hepatology*, 1-5.
- Andrade, R. J., & Tulkens, P. M., 2011), Hepatic safety of antibiotics used in primary care, *Journal of Antimicrobial Chemotherapy*, **66**(7), 1434-1436.
- Augustin, S., González, A., Genescà, J., 2010, Acute esophageal variceal bleeding: Current strategies and new perspectives, *World J Hepatol*, **2**(7), 261-262.
- Aydın, M. M., & Akçali, K. C., 2018, Liver fibrosis, *Turk J Gastroenterol*, **29**, 14-21.
- Balatandayoudam, A., Karthigeyan, R., Sathyanarayanan, R., Kumar, B.S., & Selvakumar, R., 2012, Dental considerations for patients with hepatic dysfunction, *JIDENT*, 5.
- Bang, C.S. *et al.*, 2014, Peptic ulcer disease in liver cirrhosis and chronic hepatitis impact of portal hypertension, *Scandinavian Journal of Gastroenterology*, 1-2.
- Bernardi, M., Maggioli, C., Zaccherini, G., 2012, Human albumin in the management of complications of liver cirrhosis, *Critical Care*, 1-2.
- Bemeur, C., & Butterworth, R.F., 2013, Nutrition in the Management of Cirrhosis and its Neurological Complications, *Journal of Clinical and Experimental Hepatology*, **4** (2), 143.
- Bhaargavi, V., Jyotsna, G.S.L., & Tripurana, R., 2014, A Review On Hepatoprotective Activity, *IJPSR*, **5** (3), 690-691.
- Blecker, E., 2011, Diagnosis and therapy of ascites in liver cirrhosis, *World J Gastroenterol*, **17** (10), 1237-1238.
- Bucsics, T., & Krones, E., 2017, Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome, *Gastroenterology Report*, **5**(2), 127-128.
- Butterworth, R. F., & Canbay, A., 2018, Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease, *Digestive Diseases*, 1-6.
- Cahaya, N., & Safitri, A. R. M., 2014, Evaluasi Obat-Obatan Berpotensi Hepatotoksik pada Pasien Dengan Gangguan Fungsi Hepar di Ruang

- Rawat Inap RSUD Ulin Banjarmasin, *Jurnal Pharmascience*, **2** (1), 16-24.
- Cawcutt, K. A., & Peters, S. G., 2014, Overview and Update on Management, *Mayo Clinic Proceedings*, **89** (11), 1572-1578.
- CDC, 2016, *The ABCs of Hepatitis*, Department of Health and Human Services, US, 1-2.
- Chang, P.E., Wong, G.W., Li, J.W.Q., Lui, H.F., Chow, W.C., Tan, C.K., 2015, Epidemiology and Clinical Evolution of Liver Cirrhosis in Singapore, *Annals Academy of Medicine*, **44** (6), 218-225.
- Chedid, M. L., *et al.*, 2017, Hepatocellular Carcinoma: Diagnosis and Operative Management, *ABCD Arq Bras Cir Dig*, **30** (4), 272-278.
- Cheng, Y.P., Rong, N.C., Yun, F.L, 2012, Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapy, *Elsevier*, Taiwan, 442.
- D'Amico, G., Tsao, G.G, Pagliaro L., 2006, Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies, *Journal of Hepatology*, **44**, 217-31.
- Deng, X., James P. Luyendyk, Patricia E. Ganey, and Robert A. Roth, 2009, Inflammatory Stress and Idiosyncratic Hepatotoxicity: Hints from Animal Models, *Pharmacological Reviews*, **61** (3).
- Departemen Kesehatan RI, 2007, *Pedoman Pengobatan Dasar di Puskesmas 2007*. Direktorat jenderal Bina Kefarmasian dan Alat Kesehatan Direktorat Bina Penggunaan Obat Rasional, Jakarta, 204-205.
- Departemen Kesehatan RI, 2007, *Pharmaceutical Care untuk Penyakit Hepar*, Departemen Kesehatan Republik Indonesia, Jakarta, 7-9.
- Devi, M, Senthilvel, N., Josey, D., Jetto, D.A., Harold, E., Mabel, E.V.K., 2016, Dosage Adjustments of Potentially Hepatotoxic Medications in Patients with Liver Dysfunction, *Hygeia.J.D.Med.*, **8** (1), 16-26.
- DiPiro, J. T., Schwinghammer, T. L., DiPiro, C. V., and Wells, B. G., 2009, *Pharmacotherapy Handbook*, Seventh Edition, McGraw-Hill Education, United States, 213-220.
- DiPiro, J. T., Schwinghammer, T. L., DiPiro, C. V., and Wells, B. G., 2015, *Pharmacotherapy Handbook*, 9th Edition, McGraw-Hill Education, US, 239-249.
- Durand, F., & Valla, D., 2005, Assesment of the prognosis of cirrhosis: Child Pugh vs MELD, *J. Hepatol* **42** : Suppl (1) : 100-105.
- Ehrenpreis, S., Ehrenpreis E.D., 2001, *Clinician's handbook of Prescription Drugs*, McGraw-Hill Companies.
- Franciscus, A, 2017, What is Cirrhosis?, *HCSP*, **7**, 1-3.
- Friedman, L. S., Keeffe, E. B., Dienstag, J. S., 2012, *Handbook of Liver Disease 3th Edition*, ELSEVIER, China.
- Garcia, C.D, Jaquez, Q.J.O., Gonzalez, G.J.A., Maldonado, G.H., 2009, Liver cirrhosis and diabetes: Risk factors, pathophysiology, clinical implications and management, *World J Gastroenterol*, **15**(3), 280-281.

- Gerbes, A. L., 2016, Liver Cirrhosis and Kidney, *Digestive Diseases*, **34**(4), 387–388.
- Goldis, A., Lupusoru, R., Goldis, R., Ratiu, J., 2017, Prognostic Factors in Liver Cirrhosis Patients with Upper Gastrointestinal Bleeding, *Biol Med*, **10**, 2-3.
- Gonzalez, C.R., Jones, E.A., Moreno, O.R, 2009, Spectrum of anemia associated with chronic liver disease, *World J Gastroenterol*, **15**(37), 4653.
- Green, R.M., & Flamm, S., 2002, AGA technical review of evaluation of liver chemistry tests. *Gastroenterology*, **123** (4), 1372-1373.
- Guy, J., & Peters, M. G., 2013, Liver Disease in Women: The Influence of Gender on Epidemiology, Natural History, and Patient Outcomes, *Gastroenterology & Hepatology*, (9), 633-639.
- Hagström, H., 2017, Alcohol, smoking and the liver disease patient, *Best Practice & Research Clinical Gastroenterology*, **31**(5), 537–543.
- Häner, C.S., 2008, *Dose Adaptation of Drugs in Patients with Liver Disease*, Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel, Basel, 15-46.
- Henriksen, J. H., & Møller, S, 2004, Hypertension and liver disease, *Current Hypertension Reports*, **6**(6), 453–456.
- Hickman, I.J., & Macdonald, G.A., 2007, Impact of Diabetes on the Severity of Liver Disease, *The American Journal of Medicine*, **120** (10), 829-831.
- Hilzenrat, N., & Sherker, A.V., 2012, Esophageal Varices: Pathophysiology, Approach, and Clinical Dilemmas, *International Journal of Hepatology*, 1.
- Holstein, A., Hinze, S., THIEßEn, E., Plaschke, A., & Egberts, E.H., 2002, Clinical implications of hepatogenous diabetes in liver cirrhosis, *Journal of Gastroenterology and Hepatology*, **17**(6), 678-679.
- Hung, T.H., Tseng, C.W., Hsieh, Y.H., Tseng, K.C., Tsai, C.C., & Tsai, C.C., 2013, High mortality of pneumonia in cirrhotic patients with ascites, *BMC Gastroenterology*, **13** (1), 1-2.
- Kamalaporn, P., Sobhonslidsuk, A., Jatchavala, J., Atisook, K., Rattanasiri, S., & Pramoolsinsap, C., 2005, Factors predisposing to peptic ulcer disease in asymptomatic cirrhotic patients, *Alimentary Pharmacology and Ther*, 1459-1460.
- Keshav, S., 2004, *The Gastrointestinal System at a Glance*, Blackwell Science, London, 12-28.
- Kumar, D., & Tandon, R.K., 2001, Use of ursodeoxycholic acid in liver diseases, *Journal of Gastroenterology and Hepatology*, India, **16**(1), 3–14.
- Kumar, S., Bhavana, P., Supriya, C.H., Rahaman, S.K.A., 2015, Prevalence and Drug Utilization Pattern in Hepatic Impairment Patients at a Tertiary Care Hospital, *International Journal of Science and Research (IJSR)*, **6**, 1878-1883.

- Lacy, C. F., Armstrong, L. L., Goldman, M. P., Lance, L.L., 2009, *Drug Information Handbook 17th Edition*, USA: Lexi-com, Inc.
- Lameshow, S., Hosmer, D.W., Klar, J., & Lwanga, S.K., 1990, *Adequacy of Sample Size in Health Studies*, World Health Organization, New York.
- Lee, J.S., 2005, Albumin for End-Stage Liver Disease, *korean j intern med*, **27**, 15-17.
- Lonn, E., *et al.*, 2006, Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease, *The New England Journal of Medicine*, **354**(15), 1568.
- Mishra, S., Aeri, V., & Katare, D.P., 2014, Hepatoprotective Medication for Liver Injury, *World Journal of Pharmacy and Pharmaceutical Sciences*, **3** (5), 900-901.
- Mohit, D., Parminder, N., Jaspreet, N., & Manisha, M., 2011, Hepatotoxicity V/S Hepatoprotective Agents-a Pharmacological Review, *International Research Journal of Pharmacy*, **2** (3), 31-34.
- Moore, C.M., & Thiel, D.H.V., 2013, Cirrhotic ascites review: Pathophysiology, diagnosis and management, *World J Hepatol*, **5** (5), 251-252.
- Muriel, P., & Espinoza, Y.R., 2008, Beneficial Drugs for Liver Diseases, *JOURNAL OF APPLIED TOXICOLOGY*, **28**, 93–100.
- Navarro, VJ., & Senior, J.R., 2006, Drug Related hepatotoxicity, *N England Journal Med*, **9** (354), 731.
- Oktaviani, I., 2012, Aspek Farmakokinetik Klinik Obat-Obatan yang Digunakan Pasien Sirosis Hati di Bangsal Interne RSUP Dr. M. Djamil Padang Periode Oktober 2011- Januari 2012, *Laporan Penelitian*, Padang, 3-4.
- Párraga, L.P., López, I.M., Bosch, P.V., Latorre, V.P., & Sánchez, O.D., 2012, Drug dosage recommendations in patients with chronic liver disease, *REVESPERFERMDIG*, 178.
- Pessione, F., 2001, Cigarette smoking and hepatic lesions in patients with chronic hepatitis C, *Hepatology*, **34**(1), 121–125.
- Reiberger, T., Bucsics, T., Paternostro, R., Pfisterer, N., Riedl, F., Mandorfer, M., 2018, Small Esophageal Varices in Patients with Cirrhosis—Should We Treat Them?, *Current Hepatology Reports*, **17**, 301.
- Rima, A. R., 2009, Complications of Chronic Liver Disease, *PSAP*, 91-104.
- Saito, Z., *et al.*, 2016, Effectiveness of hepatoprotective drugs for anti-tuberculosis drug-induced hepatotoxicity: a retrospective analysis, *BMC Infectious Diseases*, **16** (668), 1-3.
- Sid, V., Siow, Y. L., & O, K., 2017, Role of folate in nonalcoholic fatty liver disease, *Canadian Journal of Physiology and Pharmacology*, **95**(10), 9-10.
- Soeters, P.B., Wolfe, R.R., & Shenkin, A., 2019, Hypoalbuminemia: Pathogenesis and Clinical Significance, *Wiley Periodicals*, **43** (2), 188.

- Spinella, R., Sawhney, R., & Jalan, R., 2015, Albumin in chronic liver disease structure, functions and therapeutic implications, *Hepatology International*, **10** (1), 124–132.
- Sudoyo, A.W., Setiyohadi, B., Alwi, I., Simadibrata, M., Setiati, S., 2006, *Buku Ajar Ilmu Penyakit Dalam* Jilid I Edisi ke-4, Balai Penerbitan IPD Fakultas Kedokteran Universitas Indonesia, Jakarta, 668-672.
- Smyk, D.S., Bogdanos, D.P., Kriese, S., Billinis, C., Burroughs, A.K., & Rigopoulou, E.I., 2012, Urinary tract infection as a risk factor for autoimmune liver disease From bench to bedside, *Clinics and Research in Hepatology and Gastroenterology*, **36**, 110-117.
- Tajiri K, & Shimizu Y, 2013, Liver physiology and liver diseases in the elderly, *World J Gastroenterol*, **19** (46), 8459-8467.
- Thomson, A.B.R., Shaffer, E.A., 2012, First Principles of Gastroenterology the Basis of Disease and an Approach to Management, *Gastroenterology*, **5** (525).
- Verbeeck, R.K., 2008, Pharmacokinetics and Dosage Adjustment in Patients with Hepatic Dysfunction, *Eur J Clin Pharmacol*, **64**, 1147-1161.
- Viasus, D. *et al.*, 2011, Community-acquired pneumonia in patients with liver cirrhosis: clinical features, outcomes, and usefulness of severity scores, *Medicine*, **90**, 110–118.
- WHO, 2013, *Regional Strategy for The Prevention and Control of Viral Hepatitis*, India, 105.
- WHO, 2016, *Global Health Sector Strategy On Viral Hepatitis*, World Health Organization, Geneva, 6-7.
- WHO, 2017, *Global Hepatitis Report 2017*, World Health Organization, Perancis, viii-ix.
- Xu, L., *et al*, 2018, Pneumonia in patients with cirrhosis: risk factors associated with mortality and predictive value of prognostic models, *Respiratory Research*, **19** (242), 1-2.